TrialPloS one2024

Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.

Qiuping Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.